Jubilant Ingrevia Limited Leadership Announcement

Jubilant Ingrevia Limited recently announced the appointment of two Co-CEOs – Anil Khubchandani & Chandan Singh Sengar.

With effect from 17th May, 2022:

• Mr. Anil Khubchandani is designated as Co-CEO & Whole Time Director of Jubilant Ingrevia Limited and will also be a member of Jubilant Ingrevia Limited’s Board.
• Mr. Chandan Singh Sengar is designated as Co-CEO of Jubilant Ingrevia Limited. He is also being inducted as a permanent invitee to Jubilant Ingrevia Limited’s Board.

Both Co-CEOS, Anil Khubchandani and Chandan Singh have been veterans in the organisation and have served the company for almost 26 and 34 years respectively.

We wish success to our new co-CEOS and congratulations to the entire Team of Jubilant Ingrevia.

Jubilant Ingrevia - Q4 & FY22 Financial Results

The Board of Jubilant Ingrevia Limited met on May 17th, 2022 to approve financial results for the quarter & Financial Year ended March 31st, 2022. The Board also declared a final dividend of Rs 2.5 per equity share of Rs 1 each on the paid up capital of the company. Including Interim Dividend declared earlier during the Financial Year, the total dividend for FY’22 works out to be 500% i.e Rs 5.0 Per equity share of Rs 1 each.

Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman, Jubilant Ingrevia Limited said: “We are pleased to announce that we delivered record financial performance during FY’2022 despite facing severe second wave of pandemic at beginning of the year and then headwinds and volatility in key input raw material and energy prices since last three quarters. We also maintained steady growth in Q4’FY22.

In our Specialty Chemicals segment we delivered strong growth led by healthy demand across industry segment. We are also pleased to share that we successfully commissioned Phase-1 of Diketene and Derivatives manufacturing unit at our Gajraula facility.

In Nutrition & Health Solution we improved our profitability due to higher price realization and improved volume in North America. In Chemical Intermediates Segment, we continued the higher sales with Pharmaceutical and Agrochemical customers and recorded healthy growth in the EU. Though profitability of the Acetyls business during Q4 was impacted due to sharp and consistent correction in Acetic Acid prices impacting our inventory, the overall impact of Acetic Acid price on profitability for full year FY’22 was not significant.

Our business team continue to work closely with customers to ensure that the increase in input cost is passed on quickly and our supply chain team ensures the uninterrupted supplies and timely deliveries. Due to advancement in our new product pipelines & CDMO projects, we are pleased to revise our investment plan for growth projects to Rs. 2050 Crore, out of this we have already committed investment in projects worth Rs. 800 Crore till date and now we plan to invest about Rs. 1,250 Crore. to be committed between FY’23 & FY’24. These investments will be funded through internal accruals and all these new facilities should be ready for operations by FY’25.”

For more info  click here